The Lynx Group
Cholangiocarcinoma News

FOENIX-CCA2: Phase 2 Open-Label Study of Futibatinib in Patients with Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions

August 2020, Vol 1, No 1

Futibatinib is a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, administered as a continuous once-daily oral regimen. The FOENIX-CCA2 phase 2 clinical trial was initiated after the results from a phase 1 dose-escalation/expansion study showed the tolerability and preliminary efficacy of futibatinib in patients with intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions.1

Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, presented the phase 2 study results at the 2020 ASCO annual meeting.

“The interim analysis demonstrated that treatment with the covalently binding FGFR inhibitor futibatinib may lead to meaningful clinical benefit in patients with refractory [intrahepatic] CCA with FGFR2 gene fusions or other rearrangements,” said Dr Goyal. “In a disease with limited treatments, this drug could be an effective and well-tolerated option for patients and the oncologists that care for them.”

This single-arm, multicenter phase 2 clinical trial enrolled patients with locally advanced or metastatic unresectable intrahepatic CCA that harbors FGFR2 gene fusions or other rearrangements, disease progression after ≥1 lines of systemic therapy (including gemcitabine plus platinum-based chemotherapy), no previous FGFR inhibitor treatment, and an Eastern Cooperative Oncology Group performance status of 0 or 1.2

Patients received futibatinib 20 mg once daily until disease progression or unacceptable toxicity. The study’s primary end point was objective response rate (ORR) based on independent central radiology review. The secondary end points included disease control rate, duration of response, and safety.

A total of 103 patients were enrolled in the study. For this interim analysis, data were reported for the 67 (65%) patients with ≥6 months of follow-up. Of these 67 patients, 82.1% had tumors harboring an FGFR2 fusion. A total of 1, 2, or ≥3 previous therapy regimens were received by 44.8%, 28.4%, and 26.9% of patients, respectively.

The ORR was 34.3% (N = 23), all partial responses, and the disease control rate was 76.1%; assessment was pending for 8 patients. The median time to response to therapy was 1.6 months (range, 1.0-4.9 months), and the median duration of response was 6.2 months (range, 2.1-14.2 months).

The most common all-grade and grade ≥3 treatment-related adverse events were hyperphosphatemia (79.1%, 25.4%, respectively), diarrhea (37.3%, 0%), and dry mouth (32.8%, 0%).

All-cause grade ≥3 adverse events were reported in 73.1% of patients. A dosing delay was required in 65.7% of patients and 53.7% of patients required dose reduction; 6% of the patients discontinued treatment because of adverse events.

The investigators concluded that the preliminary data from this study demonstrate that futibatinib may be efficacious in patients with locally advanced or metastatic unresectable intrahepatic CCA harboring FGFR2 gene fusions that progress after ≥1 lines of chemotherapy.

References

  1. Meric-Bernstam F, Arkenau H, Tran B, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol. 2018;29(suppl 5):Abstract O-001.
  2. Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol. 2020;38(15_suppl):Abstract 108.

Related Items

Hot Topics on Cholangiocarcinoma and Biliary Tract Cancer Presented at ASCO 2020
By Milind Javle, MD
August 2020, Vol 1, No 1
Several hot topics were presented at the recent ASCO 2020 annual meeting about cholangiocarcinoma (CCA), which I would briefly discuss here. First, it was very exciting to see 3 important studies regarding immunotherapy for CCA, which may represent a step forward in the development of CCA therapies.
Assessing the Safety, Efficacy, and Biomarkers of Durvalumab in Chemotherapy-Naïve Patients with Advanced Biliary Tract Cancer
August 2020, Vol 1, No 1
Immunotherapies have shown early promising efficacy in some patients with biliary tract cancer. Investigators evaluated the benefit of durvalumab (Imfinzi), a PD-L1 inhibitor, with or without tremelimumab, a CTLA-4 inhibitor, plus chemotherapy with gemcitabine and cisplatin as a first-line treatment for Korean patients with biliary tract cancer. The researchers also performed an extensive biomarker analysis.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
August 2020, Vol 1, No 1
The combination of a CTLA-4 inhibitor and a PD-1 inhibitor with ipilimumab (Yervoy) and nivolumab (Opdivo) has demonstrated superior efficacy compared with single-agent anti–PD-1 therapy in a previous study of patients with advanced melanoma and renal-cell carcinoma.
Nivolumab with Chemotherapy or with Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
August 2020, Vol 1, No 1
Arandomized, phase 2 multi-institutional study compared the role of combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) versus nivolumab plus chemotherapy with gemcitabine and cisplatin in the first-line treatment of patients with advanced biliary tract cancer.
Retrospective Analysis of Post–Second-Line Chemotherapy Outcomes in Patients with Advanced or Metastatic CCA and FGFR2 Fusions
August 2020, Vol 1, No 1
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy, with an estimated incidence of 8000 to 10,000 patients annually in the United States. Chemotherapy is the most common second-line treatment with response rates of <10% and median progression-free survival (PFS) of approximately 3 to 4 months, including FOLFOX in the ABC-06 trial. Fibroblast growth factor receptor (FGFR) 2 fusions occur in 13% to 17% of patients with CCA, and multiple targeted agents are in development for patients with FGFR2 fusions. To date, the outcome of patients with CCA and FGFR2 fusions who receive standard second-line chemotherapy is unknown.
Natural History of Cholangiocarcinoma with FGFR Alterations
August 2020, Vol 1, No 1
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are emerging as promising therapeutic targets in patients with cholangiocarcinoma (CCA). A retrospective chart review, led by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, was performed in patients with CCA who had an FGFR alteration found by tumor molecular profiling as part of routine care.1 Dr Goyal presented this study at the 2020 ASCO annual meeting.
TreeTopp: Phase 2 Study of Varlitinib plus Capecitabine versus Placebo as Second-Line Therapy for Patients with Advanced or Metastatic Biliary Tract Cancer
August 2020, Vol 1, No 1
Varlitinib is a reversible small-molecule, pan human epidermal growth factor receptor (HER) inhibitor with low nanomolar potency against HER1 (EGFR), HER2, and HER4.
Phase 2 Study of Modified FOLFOX versus Modified FOLFIRI in Patients with Locally Advanced or Metastatic Biliary Tract Cancer Refractory to First-Line Chemotherapy
August 2020, Vol 1, No 1
In patients with locally advanced or metastatic biliary tract cancer, treatment with second-line chemotherapy is challenging after disease progression from first-line gemcitabine plus cisplatin, although treatment with modified FOLFOX (mFOLFOX) has been proven to be superior to active symptom control in the ABC-06 trial. Irinotecan (Camptosar) is an active drug used in the treatment of various gastrointestinal cancers.
ClarIDHy Phase 3 Study: IDH1 Mutation Detection in ctDNA and Clinical Response in Patients with Advanced Intrahepatic Cholangiocarcinoma
August 2020, Vol 1, No 1
Mutations in IDH1 are detected in approximately 13% of patients with intrahepatic cholangiocarcinoma (CCA). ClarIDHy was a global, phase 3, double-blind clinical trial in previously treated patients with advanced intrahepatic CCA with IDH1 mutation.
Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Intrahepatic Cholangiocarcinoma: Comprehensive Genomic Profiling Study
August 2020, Vol 1, No 1
Genomic alterations that are characteristic of intrahepatic cholangiocarcinoma (CCA) are well known. A study led by Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, MA, examined whether genomic alterations from a primary tumor would differ from metastatic tumor tissue and liquid biopsy in patients with intrahepatic CCA. The study results were presented at the 2020 ASCO annual meeting.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: